Macrophages in multiple myeloma: Emerging concepts and therapeutic implications

Fotis Asimakopoulos, Jaehyup Kim, Ryan A. Denu, Chelsea Hope, Jeffrey L. Jensen, Samuel J. Ollar, Ellen Hebron, Claire Flanagan, Natalie Callander, Peiman Hematti

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Multiple myeloma, a clonal plasma cell malignancy, has long provided a prototypic model to study regulatory interactions between malignant cells and their microenvironment. Myeloma-associated macrophages have historically received limited scrutiny, but recent work points to central and non-redundant roles in myeloma niche homeostasis. The evidence supports a paradigm of complex, dynamic and often mutable interactions between macrophages and other cellular constituents of the niche. We and others have shown that macrophages support myeloma cell growth, viability and drug resistance through both contact-mediated and non-contact-mediated mechanisms. These tumor-beneficial roles have evolved in opposition to, or in parallel with, intrinsic pro-inflammatory and tumoricidal properties. Thus, simple blockade of protective "don't eat me" signals on the surface of myeloma cells leads to macrophage-mediated myeloma cell killing. Macrophages also enhance the tumor-supportive role of mesenchymal stem/stromal cells (MSCs) in the niche: importantly, this interaction is bidirectional, producing a distinct state of macrophage polarization that we termed "MSC-educated macrophages." The intriguing pattern of cross-talk between macrophages, MSCs and tumor cells highlights the myeloma niche as a dynamic multi-cellular structure. Targeted reprogramming of these interactions harbors significant untapped therapeutic potential, particularly in the setting of minimal residual disease, the main obstacle toward a cure.

Original languageEnglish (US)
Pages (from-to)2112-2121
Number of pages10
JournalLeukemia and Lymphoma
Volume54
Issue number10
DOIs
StatePublished - Oct 1 2013
Externally publishedYes

Fingerprint

Multiple Myeloma
Mesenchymal Stromal Cells
Macrophages
Therapeutics
Neoplasms
Cellular Microenvironment
Residual Neoplasm
Cellular Structures
Plasma Cells
Drug Resistance
Cell Survival
Homeostasis
Growth

Keywords

  • Immunotherapeutic approaches
  • Immunotherapy
  • Monocyte and macrophage biology
  • Monocytes
  • Myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Asimakopoulos, F., Kim, J., Denu, R. A., Hope, C., Jensen, J. L., Ollar, S. J., ... Hematti, P. (2013). Macrophages in multiple myeloma: Emerging concepts and therapeutic implications. Leukemia and Lymphoma, 54(10), 2112-2121. https://doi.org/10.3109/10428194.2013.778409

Macrophages in multiple myeloma : Emerging concepts and therapeutic implications. / Asimakopoulos, Fotis; Kim, Jaehyup; Denu, Ryan A.; Hope, Chelsea; Jensen, Jeffrey L.; Ollar, Samuel J.; Hebron, Ellen; Flanagan, Claire; Callander, Natalie; Hematti, Peiman.

In: Leukemia and Lymphoma, Vol. 54, No. 10, 01.10.2013, p. 2112-2121.

Research output: Contribution to journalReview article

Asimakopoulos, F, Kim, J, Denu, RA, Hope, C, Jensen, JL, Ollar, SJ, Hebron, E, Flanagan, C, Callander, N & Hematti, P 2013, 'Macrophages in multiple myeloma: Emerging concepts and therapeutic implications', Leukemia and Lymphoma, vol. 54, no. 10, pp. 2112-2121. https://doi.org/10.3109/10428194.2013.778409
Asimakopoulos, Fotis ; Kim, Jaehyup ; Denu, Ryan A. ; Hope, Chelsea ; Jensen, Jeffrey L. ; Ollar, Samuel J. ; Hebron, Ellen ; Flanagan, Claire ; Callander, Natalie ; Hematti, Peiman. / Macrophages in multiple myeloma : Emerging concepts and therapeutic implications. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 10. pp. 2112-2121.
@article{c47c8a5b56be4820b13ff0f87d3680ba,
title = "Macrophages in multiple myeloma: Emerging concepts and therapeutic implications",
abstract = "Multiple myeloma, a clonal plasma cell malignancy, has long provided a prototypic model to study regulatory interactions between malignant cells and their microenvironment. Myeloma-associated macrophages have historically received limited scrutiny, but recent work points to central and non-redundant roles in myeloma niche homeostasis. The evidence supports a paradigm of complex, dynamic and often mutable interactions between macrophages and other cellular constituents of the niche. We and others have shown that macrophages support myeloma cell growth, viability and drug resistance through both contact-mediated and non-contact-mediated mechanisms. These tumor-beneficial roles have evolved in opposition to, or in parallel with, intrinsic pro-inflammatory and tumoricidal properties. Thus, simple blockade of protective {"}don't eat me{"} signals on the surface of myeloma cells leads to macrophage-mediated myeloma cell killing. Macrophages also enhance the tumor-supportive role of mesenchymal stem/stromal cells (MSCs) in the niche: importantly, this interaction is bidirectional, producing a distinct state of macrophage polarization that we termed {"}MSC-educated macrophages.{"} The intriguing pattern of cross-talk between macrophages, MSCs and tumor cells highlights the myeloma niche as a dynamic multi-cellular structure. Targeted reprogramming of these interactions harbors significant untapped therapeutic potential, particularly in the setting of minimal residual disease, the main obstacle toward a cure.",
keywords = "Immunotherapeutic approaches, Immunotherapy, Monocyte and macrophage biology, Monocytes, Myeloma",
author = "Fotis Asimakopoulos and Jaehyup Kim and Denu, {Ryan A.} and Chelsea Hope and Jensen, {Jeffrey L.} and Ollar, {Samuel J.} and Ellen Hebron and Claire Flanagan and Natalie Callander and Peiman Hematti",
year = "2013",
month = "10",
day = "1",
doi = "10.3109/10428194.2013.778409",
language = "English (US)",
volume = "54",
pages = "2112--2121",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Macrophages in multiple myeloma

T2 - Emerging concepts and therapeutic implications

AU - Asimakopoulos, Fotis

AU - Kim, Jaehyup

AU - Denu, Ryan A.

AU - Hope, Chelsea

AU - Jensen, Jeffrey L.

AU - Ollar, Samuel J.

AU - Hebron, Ellen

AU - Flanagan, Claire

AU - Callander, Natalie

AU - Hematti, Peiman

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Multiple myeloma, a clonal plasma cell malignancy, has long provided a prototypic model to study regulatory interactions between malignant cells and their microenvironment. Myeloma-associated macrophages have historically received limited scrutiny, but recent work points to central and non-redundant roles in myeloma niche homeostasis. The evidence supports a paradigm of complex, dynamic and often mutable interactions between macrophages and other cellular constituents of the niche. We and others have shown that macrophages support myeloma cell growth, viability and drug resistance through both contact-mediated and non-contact-mediated mechanisms. These tumor-beneficial roles have evolved in opposition to, or in parallel with, intrinsic pro-inflammatory and tumoricidal properties. Thus, simple blockade of protective "don't eat me" signals on the surface of myeloma cells leads to macrophage-mediated myeloma cell killing. Macrophages also enhance the tumor-supportive role of mesenchymal stem/stromal cells (MSCs) in the niche: importantly, this interaction is bidirectional, producing a distinct state of macrophage polarization that we termed "MSC-educated macrophages." The intriguing pattern of cross-talk between macrophages, MSCs and tumor cells highlights the myeloma niche as a dynamic multi-cellular structure. Targeted reprogramming of these interactions harbors significant untapped therapeutic potential, particularly in the setting of minimal residual disease, the main obstacle toward a cure.

AB - Multiple myeloma, a clonal plasma cell malignancy, has long provided a prototypic model to study regulatory interactions between malignant cells and their microenvironment. Myeloma-associated macrophages have historically received limited scrutiny, but recent work points to central and non-redundant roles in myeloma niche homeostasis. The evidence supports a paradigm of complex, dynamic and often mutable interactions between macrophages and other cellular constituents of the niche. We and others have shown that macrophages support myeloma cell growth, viability and drug resistance through both contact-mediated and non-contact-mediated mechanisms. These tumor-beneficial roles have evolved in opposition to, or in parallel with, intrinsic pro-inflammatory and tumoricidal properties. Thus, simple blockade of protective "don't eat me" signals on the surface of myeloma cells leads to macrophage-mediated myeloma cell killing. Macrophages also enhance the tumor-supportive role of mesenchymal stem/stromal cells (MSCs) in the niche: importantly, this interaction is bidirectional, producing a distinct state of macrophage polarization that we termed "MSC-educated macrophages." The intriguing pattern of cross-talk between macrophages, MSCs and tumor cells highlights the myeloma niche as a dynamic multi-cellular structure. Targeted reprogramming of these interactions harbors significant untapped therapeutic potential, particularly in the setting of minimal residual disease, the main obstacle toward a cure.

KW - Immunotherapeutic approaches

KW - Immunotherapy

KW - Monocyte and macrophage biology

KW - Monocytes

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=84884493350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884493350&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.778409

DO - 10.3109/10428194.2013.778409

M3 - Review article

C2 - 23432691

AN - SCOPUS:84884493350

VL - 54

SP - 2112

EP - 2121

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -